Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In the study by Bala and colleagues,1 it seems that interpretations on cost effectiveness of palivizumab are made based on the number of admissions for bronchiolitis alone.
We conducted an epidemiological study to determine the importance of respiratory syncytial virus (RSV) in the region on 412 …